Leukemia

Ba/F3 cell lines engineered to express Y572C showed reduced cell viability when exposed to different concentrations of midostaurin [IC50 (nm) 0.84] (no Figure available, data presented in supplemental… (full text at CIViC)

PMID 39806020 · Anabtawi et al., 2025 · Open in CIViC

EID: 12788: Ba/F3 cell lines engineered to express Y572C showed reduced cell viability when exposed to different concentrations of quizartinib [IC50 (nm) 0.06] (no Figure available, data presented in … (full text at CIViC)

PMID 39806020 · Anabtawi et al., 2025 · Open in CIViC

Ba/F3 cell lines engineered to express Y572C showed reduced cell viability when exposed to different concentrations of sorafenib [IC50 (nm) 0.41] (no Figure available, data presented in supplemental t… (full text at CIViC)

PMID 39806020 · Anabtawi et al., 2025 · Open in CIViC

A pBABE expression vector with wild-type FLT3 was subjected to site-directed mutagenesis to introduce single amnio acid deletions across the juxtamembrane domain then transfected into Ba/F3 cells to c… (full text at CIViC)

PMID 33914060 · Young et al., 2021 · Open in CIViC

Ba/F3 cell lines expressing the variant FLT3 Y572del showed sensitivity to crenolanib comparable to the FLT3-ITD construct (Figure 4).

PMID 33914060 · Young et al., 2021 · Open in CIViC

Single strand polymorphism targeting FLT3 in addition to RUNX1, KIT, CEBPA, PTPN11, and NRAS was carried out to identify novel recurring gene mutations in an acute myeloid leukemia cohort comprised of… (full text at CIViC)

PMID 15667533 · Smith et al., 2005 · Open in CIViC

In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC)

PMID 27099147 · Uras et al., 2016 · Open in CIViC

In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC)

PMID 15459012 · Fiedler et al., 2005 · Open in CIViC

With vitro proliferation assay in Ba/F3 cells, it was found that the cells bearing FLT3-ITD Y693C/N exhibited >10-fold resistance to Gilteritinib. Similar resistance was found in cells bearing FLT3-IT… (full text at CIViC)

PMID 32040554 · Tarver et al., 2020 · Open in CIViC

The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib a… (full text at CIViC)

PMID 22858906 · Williams et al., 2013 · Open in CIViC

A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC)

PMID 22858906 · Williams et al., 2013 · Open in CIViC

Single strand polymorphism targeting FLT3 in addition to RUNX1, KIT, CEBPA, PTPN11, and NRAS was carried out to identify novel recurring gene mutations in an acute myeloid leukemia cohort comprised of… (full text at CIViC)

PMID 15667533 · Smith et al., 2005 · Open in CIViC

FOXP1-ABL1 fusion was identified in Ph-like ALL

PMID 31935290 · Harvey et al., 2020 · Open in CIViC

This study investigates the diagnostic importance of the translocation t(16;21)(p11;q22), resulting in the TLS/FUS::ERG fusion gene, in acute myeloid leukemia (AML). The authors utilized RT-PCR to det… (full text at CIViC)

PMID 9242552 · Kong et al., 1997 · Open in CIViC

This international retrospective study investigates the diagnostic features of acute myeloid leukemia (AML) with the t(16;21) translocation resulting in the FUS::ERG fusion gene in pediatric patients.… (full text at CIViC)

PMID 30150206 · Noort et al., 2018 · Open in CIViC

Children with Down syndrome are at increased risk to developing Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia associated with Down Syndrome (ML-DS). GATA1, a gene that encodes an essentia… (full text at CIViC)

PMID 27069254 · Arber et al., 2016 · Open in CIViC

We report an additional case of twin-to-twin transmission of a TAM clone with identical GATA1 exon 2 mutations in monochorionic-diamniotic twin infants without constitutional T21. This case along with… (full text at CIViC)

PMID 32464589 · Roseman et al., 2020 · Open in CIViC

GATA2 ZF1 mutations are associated with distinct clinico-biological features and predict better prognosis, different from zinc finger 1 mutations, in AML patients. ZF1 mutations were closely associate… (full text at CIViC)

PMID 30190467 · Tien et al., 2018 · Open in CIViC

In a retrospective study of 144 patients with B-cell chronic lymphocytic leukemia, the median progression-free survival was significantly different between GNAS T393C genotypes (TT 130 months; TC 100 … (full text at CIViC)

PMID 17020971 · Frey et al., 2006 · Open in CIViC

I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%.

PMID 29860938 · DiNardo et al., 2018 · Open in CIViC

Phase 3 trial of 146 patients randomized to either IDH1 inhibitor ivosidenib and azacitidine or azacitidine and placebo revealed significantly longer event-free survival in the ivosidenib-group. Patie… (full text at CIViC)

PMID 35443108 · Montesinos et al., 2022 · Open in CIViC

Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation.

PMID 20805365 · Schnittger et al., 2010 · Open in CIViC

In this post hoc long-term follow-up of the phase 3 AGILE trial (NCT03173248; median follow-up 28.6 months; n=148), IDH1 R132 mutations served as the obligate driver alteration defining patient eligib… (full text at CIViC)

PMID 40706052 · Montesinos et al., 2025 · Open in CIViC

In the phase 3 AGILE trial enrolling patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction chemotherapy, IDH1 R132 mutations (confirmed by FDA-approved Abbott Real… (full text at CIViC)

PMID 35443108 · Montesinos et al., 2022 · Open in CIViC

IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation.

PMID 20538800 · Abbas et al., 2010 · Open in CIViC